MX9705969A - Novel farnesyl transferase inhibitors, preparation thereof, and pharmaceutical compositions containing same. - Google Patents
Novel farnesyl transferase inhibitors, preparation thereof, and pharmaceutical compositions containing same.Info
- Publication number
- MX9705969A MX9705969A MX9705969A MX9705969A MX9705969A MX 9705969 A MX9705969 A MX 9705969A MX 9705969 A MX9705969 A MX 9705969A MX 9705969 A MX9705969 A MX 9705969A MX 9705969 A MX9705969 A MX 9705969A
- Authority
- MX
- Mexico
- Prior art keywords
- radical
- alkyl
- optionally substituted
- hydrogen atom
- grouping
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Novel farnesyl transferase inhibitors of general formula (I), preparation thereof, and pharmaceutical compositions containing same. In general formula (I), R1 is Y-S-A1- (where Y is a hydrogen atom, an amino acid residue, a fatty acid residue, an alkyl or alkoxycarbonyl radical, or a radical R4-S-, where R4 is a C1-6 alkyl radical optionally substituted by a phenyl radical, or a radical of general formula (II), wherein A1, X1, Y1, R2, R'2, X2, Y2, X, R3, R'3 and R are as defined below, and A1 is a C1-4 alkylene radical optionally 'alpha'-substituted in the >C(X1)(Y1) grouping by an amino, alkylamino, alkanoylamino or alkoxycarbonylamino radical); X1 and Y1 are each a hydrogen atom or, taken together with the carbon atom to which they are attached, a >C=O grouping; R2 is a straight or branched C1-4 alkyl radical optionally substituted by a cyclohexyl radical; R'2 is hydrogen or alkyl; X2 and Y2 are each a hydrogen atom or, taken together with the carbon atom to which they are attached, a >C=O grouping; R3 is a C1-4 alkyl radical optionally substituted by hydroxy, alkoxy, mercapto, alkylthio, alkylsulphinyl or alkylsulphonyl, with the proviso that, when R3 is an alkyl radical substituted by a hydroxy radical, R3 may form a lactone with the 'alpha'-carboxy radical; R'3 is hydrogen or alkyl; X is an oxygen or sulphur atom; and R is a hydrogen atom or an optionally substituted alkyl radical or an optionally substituted phenyl radical. These novel products have anticancer properties.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9501490A FR2730492B1 (en) | 1995-02-09 | 1995-02-09 | NOVEL FARNESYL TRANSFERASE INHIBITORS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| FR95/01490 | 1995-02-09 | ||
| FR9501490 | 1995-02-09 | ||
| PCT/FR1996/000199 WO1996024612A1 (en) | 1995-02-09 | 1996-02-07 | Novel farnesyl transferase inhibitors, preparation thereof, and pharmaceutical compositions containing same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX9705969A true MX9705969A (en) | 1997-11-29 |
| MXPA97005969A MXPA97005969A (en) | 1998-07-03 |
Family
ID=
Also Published As
| Publication number | Publication date |
|---|---|
| NO973607L (en) | 1997-08-05 |
| TR199700726T1 (en) | 1998-01-21 |
| JPH10513468A (en) | 1998-12-22 |
| CZ249997A3 (en) | 1997-11-12 |
| ZA961073B (en) | 1996-08-20 |
| FI973279A0 (en) | 1997-08-08 |
| CN1173873A (en) | 1998-02-18 |
| WO1996024612A1 (en) | 1996-08-15 |
| SK108897A3 (en) | 1997-12-10 |
| FR2730492B1 (en) | 1997-03-14 |
| AU4722896A (en) | 1996-08-27 |
| FI973279A (en) | 1997-08-08 |
| BR9607318A (en) | 1997-12-30 |
| KR19980702049A (en) | 1998-07-15 |
| NO973607D0 (en) | 1997-08-05 |
| EP0808329A1 (en) | 1997-11-26 |
| CA2210953A1 (en) | 1996-08-15 |
| FR2730492A1 (en) | 1996-08-14 |
| PL321710A1 (en) | 1997-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2742195A (en) | Novel farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing same | |
| NO973607L (en) | New farnesyl transferase inhibitors, their preparation and preparations containing the inhibitors | |
| NO973608L (en) | New farnesyl transferase inhibitors, their preparation and pharmaceutical preparations containing the compounds | |
| IL116251A0 (en) | Transfecting agents and their pharmaceutical applications | |
| GR3030183T3 (en) | Derivatives of valproic and 2-valproenoic acid amides and use as anticonvulsants. | |
| MX9603314A (en) | Compositions containing micronized nebivolol. | |
| WO2004022625A8 (en) | Silane-crosslinkable coating formulations | |
| WO2002059102A3 (en) | Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and use | |
| BR9712807A (en) | high-viscosity complex alcohol esters | |
| ES2187025T3 (en) | NEW IRON BURNING AGENTS (III) VIA ORAL ASSETS. | |
| MXPA03000547A (en) | Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder. | |
| ES8705418A1 (en) | Substituted heterocyclic acrylic acids and esters, their preparation and pharmaceutical compositions containing them. | |
| GR3025280T3 (en) | Novel vitamin d analogues. | |
| AU2892999A (en) | Azatricyclo(3.3.1.1) decane derivatives and pharmaceutical compositions containing them | |
| BG103194A (en) | Pharmaceutical products for the treatment and prevention of diseases caused by the impairment of the vascular endothelial cells | |
| MX9705270A (en) | Novel farnesyl transferase inhibitors, preparation thereof and pharmaceutical compositions containing same. | |
| WO2001051004A3 (en) | Anti-cancer agent containing naphthoquinone compound | |
| ES8704081A1 (en) | 3-Alcoxy-2-(N-pyrrolidino)-N-pyridyl-N-furyl(or thienyl)-methyl propyl amines, their preparation and pharmaceutical compositions containing them. | |
| MX9606106A (en) | Novel farnesyl transferase inhibitors, their preparation and pharmaceutical compositions containing same. | |
| AU4900499A (en) | Use of amino azoic dyes as markers of oil distillation products | |
| AU2003260827A8 (en) | Methods and compositions for in vitro synthesis of biological macromolecules in a cell-free system enriched with atp-sulfurylase | |
| BG100704A (en) | New piperazine derivatives and methods for their preparation as well as of the compounds containing them | |
| ES2001107A6 (en) | Perfume compositions and perfumed articles and materials which contain derivatives of m-cresol as perfume component. | |
| ES8801238A1 (en) | Unsaturated esters of furoic acid and method for their preparation. | |
| SU1455686A1 (en) | Anaerobic sealing composition |